%D8%B3%D9%8A%D8%AA%D8%A7%D8%B1%D8%A7%D8%A8%D9%8A%D9%86%D8%B3%DB%8C%D8%AA%D8%A7%D8%B1%D8%A7%D8%A8%DB%8C%D9%86CitarabinaCytarabinCytarabinCytarabineCitarabina%D8%B3%DB%8C%D8%AA%D8%A7%D8%B1%D8%A7%D8%A8%DB%8C%D9%86SytarabiiniCytarabine%D7%A6%D7%99%D7%98%D7%A8%D7%91%D7%99%D7%9F%D5%91%D5%AB%D5%BF%D5%A1%D6%80%D5%A1%D5%A2%D5%AB%D5%B6Citarabina%E3%82%B7%E3%82%BF%E3%83%A9%E3%83%93%E3%83%B3%E0%AC%B8%E0%AC%BE%E0%AC%87%E0%AC%9F%E0%AC%BE%E0%AC%B0%E0%AC%BE%E0%AC%AC%E0%AC%BF%E0%AC%A8Arabinozyd_cytozynyCitarabin%C4%83%D0%A6%D0%B8%D1%82%D0%B0%D1%80%D0%B0%D0%B1%D0%B8%D0%BDCitarabinCitarabinCitarabin%D0%A6%D0%B8%D1%82%D0%B0%D1%80%D0%B0%D0%B1%D1%96%D0%BDCytarabineQ180983%E9%98%BF%E7%B3%96%E8%83%9E%E8%8B%B7
about
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaSequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaAn Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationA Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationClinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell LymphomaBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaA Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or LymphomasAcalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell LymphomaComparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaA Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaFludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaSMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCombination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesOxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLGleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesR-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaResearch Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell TransplantationTimed-Sequential Induction in CBF-AMLUmbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseStandard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCombination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaCombination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic SyndromesT Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsSafety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaClofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative NeoplasmStudy of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell LymphomaPhase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromePooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchA Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic LymphomaEfficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLPilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger PatientsStudy of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for LymphomaCytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid LeukemiaCombination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
P4844
Therapies for acute myeloid leukemia: vosaroxin.Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expressionLow frequency of pre-treatment and post-treatment haematological abnormalities in dogs with non-infectious meningoencephalitis treated with cytosine arabinoside and prednisoloneCytarabine-Resistant -ITD Leukemia Cells are Associated with Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of CabozantinibGenetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patientsR-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDYObservation of clinical efficacy and toxic and side effects of pirarubicin combined with cytarabine on acute myeloid leukemia
P921
Q1138590-E6246127-B149-4A1B-B33D-C418BBDB68ECQ208414-23321E96-B21A-4865-BA7F-28F7F701D68AQ2626074-39971831-3372-4A9C-A5BB-FCB3803AFE23Q264118-E84DAD1D-8914-41A6-A29D-E29A4F357B45Q268713-36CDF092-B9D7-4B0C-8208-7DFB779140ACQ29496-CAF71E10-4301-4E1D-83A7-FDEDE3716FD9Q369157-15545F00-0DCB-4E8E-A669-E6BE6A2189C3Q954625-0B20AB9B-C83B-4540-B072-2C76659DE84BQ976388-934018F1-0346-4F70-81D6-0555539F1E94
P2176
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Citarabin
@sh
Citarabin
@sl
Citarabina
@es
Citarabină
@ro
Cytarabin
@de
Cytarabin
@lb
Cytarabine
@nl
Cytarabine
@vi
Cytarabín
@sk
Sytarabiini
@fi
type
label
Citarabin
@sh
Citarabin
@sl
Citarabina
@es
Citarabină
@ro
Cytarabin
@de
Cytarabin
@lb
Cytarabine
@nl
Cytarabine
@vi
Cytarabín
@sk
Sytarabiini
@fi
altLabel
1-beta-D-Arabinofuranosylcytosine
@cy
1-beta-D-Arabinofuranosylcytosine
@en
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
@cy
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
@en
Ara-C
@fr
Aracytine
@fr
Citarabina
@en
Cytarabine
@en
Cytarabinum
@en
Cytosar®
@cy
prefLabel
Citarabin
@sh
Citarabin
@sl
Citarabina
@es
Citarabină
@ro
Cytarabin
@de
Cytarabin
@lb
Cytarabine
@nl
Cytarabine
@vi
Cytarabín
@sk
Sytarabiini
@fi